Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | GOT1 | P17174 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879049 | 0.76 | GPR3 (0.44) | GPR3TGFBR1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL20265361 | 0.76 | ALDH1A1 (0.47) | GPR3TGFBR1CYP1A2HDAC3HDAC1 | |
| SCHEMBL1998929 | 0.75 | PABPC1 (0.41) | GPR3TGFBR1CYP1A2HDAC3HDAC1 | |
| SCHEMBL2002462 | 0.73 | HTR1A (0.58) | HDAC3HDAC1SMN1; SMN2HTR1AADRA1D | |
| SCHEMBL1116308 | 0.73 | KDM1A (0.48) | GPR3SMN1; SMN2ALDH1A1KDM4ETP53 | |
| SCHEMBL2009242 | 0.72 | GPR3 (0.44) | GPR3TGFBR1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL19841858 | 0.71 | IDO1 (0.43) | GPR3TGFBR1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL1996604 | 0.69 | ADRA2A (0.53) | GPR3SMN1; SMN2ALDH1A1KDM4EADRA1A | |
| SCHEMBL13134233 | 0.69 | PTPN1 (0.62) | HDAC3HDAC1LMNABTKPTPN1 | |
| SCHEMBL276531 | 0.69 | GPR3 (0.50) | GPR3TGFBR1CYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960402-B2 | Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-1795527-B1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | GPR3 2618/4885TGFBR1 3278/4885CYP1A2 333/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | GPR3 18/4885TGFBR1 1640/4885CYP1A2 1037/4885 |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | GPR3 151/4885TGFBR1 2003/4885CYP1A2 3205/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | GPR3 2618/4885TGFBR1 3278/4885CYP1A2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.